RxDoctor Payments DataLook up a doctor →

Peter Saccone, DO

Pulmonary Disease · Linwood, NJNPI 1295066181

Payments from drug & device makers

$149,383in general payments, 2019–2025

Across 1,159 payments — averaging $128.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$65K
  • AstraZeneca$55K
  • Mylan Specialty L.p.$16K
  • Viatris Specialty LLC$4K
  • Sanofi$1K
  • Regeneron Healthcare Solutions, Inc.$775
  • plus $7K from 36 others

What the payments were for

  • Consulting fees$4,6583%
  • Speaking & faculty fees$124,72783%
  • Travel & lodging$1,2361%
  • Food & beverage$18,34912%
  • Education$4130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$149,383 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$263,226
Medicare patients
361
Services billed
2,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter632$584,350
Dupixent PenDupilumab53$201,168
OpsumitMacitentan12$151,198
Dupixent SyringeDupilumab38$139,945
Breztri AerosphereBudesonide/Glycopyr/Formoterol108$101,299
Breo ElliptaFluticasone/Vilanterol153$91,034
Spiriva RespimatTiotropium Bromide113$80,826
NucalaMepolizumab13$46,415
SymbicortBudesonide/Formoterol Fumarate99$24,796
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$20,660
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$20,051
Albuterol Sulfate HfaAlbuterol Sulfate434$16,070
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate73$13,750
Incruse ElliptaUmeclidinium Bromide34$13,300
Fluticasone-SalmeterolFluticasone Propion/Salmeterol63$12,951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta$65,274$765,174907 claims
Actelion Pharmaceuticals US, Inc.Opsumit$28$151,19812 claims
AstraZenecaBreztri Aerosphere, Symbicort$55,273$126,096207 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$759$100,877136 claims
Axsome Therapeutics, Inc.Sunosi$306$12,70013 claims
MerckDulera$29$10,44723 claims
Covis Pharma GmbHAlvesco$41$7,11311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Linwood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →